Published in final edited form as:
Bioorg Med Chem. 2009 February 1; 17(3): 1152–1157. doi:10.1016/j.bmc.2008.12.042.

Function-Oriented Synthesis Applied to the Anti-botulinum Natural Product Toosendanin

Yuya Nakai[a,b], **William H. Tepp**[c], **Tobin J. Dickerson**[a,d], **Eric A. Johnson**[c], and **Kim D. Janda**[a,b,d,*]

a *Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA*

b *Department of Immunology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA*

c *Food Research Institute, University of Wisconsin, 1925 Willow Drive, Madison, WI 53706, USA*

d *Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA*

Abstract

Botulinum neurotoxins (BoNTs) are the etiological agents responsible for botulism, a disease characterized by peripheral neuromuscular blockade and a characteristic flaccid paralysis of humans. The natural product toosendanin is traditional Chinese medicine that has reported antibotulinum properties in animal models. To establish what chemical functionalities are necessary for the antibotulinum properties found within toosendanin, a study was initiated with the goal of using function-oriented synthesis (FOS) as a strategy to begin to unravel toosendanin's powerful anti-botulinum properties. From these studies a new synthetic strategy is put forth allowing access to a 4-acetoxy CD fragment analogue (**14**) of toosendanin, which was achieved from mesityl oxide and acetylacetone in 14-steps. Animal studies on this fragment are also reported.

Keywords

Botulinum neurotoxins; Toosendanin; Function-oriented synthesis (FOS); 4-Acetoxy CD fragment

1. Introduction

Clostridium botulinum is a rod-shaped, Gram positive, sporulating anaerobic bacillus that is widely distributed in the environment.[1] The spores, which are resistant to heat, desiccation, chemicals, radiation and oxygen, facilitate survival for very long periods. Under anaerobic conditions, and in the correct nutritional environment, spore germination and cell division take place. The global distribution of *C. botulinum* in the environment varies widely. The botulinum neurotoxins (BoNTs) comprise a family of seven immunologically distinct proteins synthesized primarily by strains of the anaerobic bacteria. These toxins (BoNT A–G) are the most lethal poisons known, with BoNT serotype A having a LD_{50} for a 70 kg human of a mere

*Corresponding author. Tel.: +1 858 784 2516; fax: +1 858 784 2595; e-mail: kdjanda@scripps.edu (K. D. Janda).

0.8 μg by inhalation.[2] Historically associated with food poisoning, these proteinaceous toxins inhibit the release of acetylcholine at neuromuscular junctions by cleavage of SNARE proteins, resulting in progressive flaccid paralysis.[3–4] It is as a result of this potent neurotoxic activity that BoNTs are of substantial concern as potential bioterrorist weapons.[5–7]

2. Results and Discussion

We have embarked on a program to identify new small molecule inhibitors of BoNT/A that are non-proteinaceous in nature and that work by a different mechanism other than inhibiting the catalytic light chain of the BoNT/A protease.[8] Limonoids, **1**, are tetranortriterpenoids with a 4,4,8-trimethylfuranylsteroid skeleton (Fig. 1) derived from euphane or tirucallane triterpenoids, and, in general, have intense bitter taste.[9] Meliaceae plants are a rich source of limonoids. Limonoids from the neem tree *Melia azadirachta indica* and the bead tree *M. azedarach* have been well studied, mainly because of their marked insect anti-feedant properties.[10] Along this same vein of research, *M. toosendan*, which is native to China and known to contain limonoid constituents, has been found to possess effective antihelmintics.[11] A major limonoid constituent found in *Melia toosendan* is the compound toosendanin, (**2**, Fig. 1), which appears to have multiple modes of action in insects including damage to midgut tissues, inhibition of esterases, cytochrome P450-aldrin epoxidase and proteinase activities.[12]

Toosendanin from a structural diversity standpoint is a fascinating molecule. The core carbon skeleton of toosendanin, is comprised of a cyclopentanoperhydrophenanthrene (**3**, Fig. 2), a molecular framework that consists of four fused, non-planar rings (labeled A–D) and a densely pack core of 14 stereocenters. Interestingly, this framework is commonly found in all mammalian steroids and hormones. What has intrigued us besides toosendanin's anti-parasitic properties are two reports in the 1980's describing toosendanin as also having anti-botulinum properties.[13] Strikingly, these findings have remained dormant, as little research has been conducted upon this molecule from a synthetic standpoint.

To probe toosendanin's anti-botulinum properties two tactics were envisioned. The first being a total synthesis of the molecule that ultimately would allow derivatives to be assessed, and thus a means to explore toosendanin's structure in relationship to its biological activity. A second was what Wender has termed Function-Oriented Synthesis (FOS).[14] Because of the complexity of toosendanin and the insurmountable odds of a total synthesis that would provide large quantities of this natural product or closely related derivatives we have set a course on investigating this molecule from a FOS standpoint. The underpinnings of FOS are that the function of a biologically active lead structure can be emulated, tuned, or possibly improved by replacement with simpler scaffolds designed to embrace the key activity-determining structural features of the natural product. Because it is unknown which elements and/or structural features impact toosendanin's biological activity we have decided to break the molecule into two fragments consisting of the AB and CD rings. In this paper, we report our initial work exploring the CD ring of toosendanin and its potential biological function.

We envisioned any synthesis emulating the CD rings of toosendanin, would need to incorporate the epoxide moiety, shared by rings C and D at the C-14 and C-15 positions. This functionality we hypothesized to be crucial, as this moiety is not observed within any steroidal skeletons, including mammalian or plant (Fig. 1). While the epoxide was deemed critical, the furan ring was not, as we have found through semi-synthesis efforts (Janda et al. unpublished results) that this ring in a reduced chemical state did not alter the molecules biological activity. Furthermore, this functionality was readily susceptible to both oxidation and reduction conditions, which would clearly hamper any practical synthesis of an abbreviated structure if included within our synthetic scheme (Janda et al. unpublished data).

Overall, there are few *de novo* synthetic efforts that describe the successful syntheses of similar limonoids or key structural fragments. Selected examples are dumsin[15] and fragments of epoxyazadiradione.[16] Our FOS approach would build on the teachings of Mateos, et al., who has recently described a synthesis of the limonoid fragment **4** in 10 steps with an overall yield of 44% (Fig. 3).[17]

We envisioned four crucial cyclization steps in the synthesis of a FOS toosendanin CD fragment: the Robinson annulation, an aldol condensation, the Nazarov cyclization, and an epoxidation reaction. Using these series of reactions it was envisioned that at various stages appropriate substituents could be embedded within the CD ring. Importantly, this approach would enable the first synthesis of the CD ring fragment of toosendanin correctly displaying all heteroatom substituents found within the natural product. Finally it is worth noting that a previous paper focusing on the reaction scope within limonoid construction has considered the possibility of building such a desired fragment, however, no compound bearing the α-acetoxy ketone functionality within ring C was reported.[18]

In developing a synthesis, our starting point featured a Robinson-type annulation of mesityl oxide **5** and acetylacetone **6** using BF_3 as a catalyst, which bestowed α-cyclocitral (Scheme 1).[16, 18] It is appropriate to note that α-cyclocitral **7** has been a preparatory material for many liminoid derivatives, particularly for SAR studies of insect antifeedant development.[16–22] The convenience of starting with **7** is most certainly due to the fact that it can be readily synthesized on a multi-gram scale with inexpensive starting materials. Selective reduction[16] of the conjugated carbonyl of diketone **7** using $NaBH_4/CeCl_3$ at −40 °C furnished the hydroxyketone **8**, which could then be utilized for epoxidation with *m*-chloroperbenzoic acid affording **9**. Aldol condensation of **9** with benzaldehyde provided dihydroxyketone **10** in 89% overall yield from **7**.

With dihydroxyketone **10**, a Nazarov electrocyclization reaction was envisioned. For comparative purposes we note that the Nazarov electrocyclization reaction of **a, b,** and **c** (Fig. 4) in the presence of acid grants the corresponding cyclization compounds.[18, 22] In lieu of these reports, we attempted the reaction of **d** with acid for the synthesis of a "non-functionalized" moiety at C3, however, this reaction failed. It is well understood that to accomplish the required cyclization a keto-group at C4, and a phenyl group at C3 are needed; unfortunately these requirements limit diversity, and as stated also dictate the stereochemical outcome.

Thus, the Nazarov electrocyclization reaction of **10** in the presence of acid granted **11a** and **11b** (inseparable), **11c**, and **11d**. We were pleased to observe taht the cyclization exclusively formed the *cis*-fused product,[17–18, 21, 23] placing the core ring system in the desired geometry of toosendanin. Reduction of the unsaturated C-ring by catalytic hydrogenation supplied compound **12a** and **12b** (inseparable), **12c**, and **12d** respectively (Scheme 2). We attempted the asymmetric reduction of **11a–d** with a plethora of reagents [for example, (2*S*,5*S*)-(−)-5-benzyl-3-methyl-2-(5-methyl-2-furyl)-4-imidazolidi-none, binaphthyl derivatives, to name a few] that would have provided the correct C3-stereocenter, but, unfortunately the lone reaction that succeeded was palladium-carbon.

The relative stereochemistry of each of these compounds was determined by 2D-ROESY spectrum (Fig. 5). Thus, for **12a**'s ROESY correlation was seen between H-4 (geminal with the acetoxy group) and Me-7 (axial); H-3 (geminal with the phenyl group) and Me-3a (the angular methyl group); Me-3a and H-7a. For the case with **12b**, we could see a correlation [(sv between H-3 and Me-3a; Me-3a and H-7a; for **12c**, H-3 and Me-3a and H-7a; H-4 and Me-7 (axial); H-5 and Me-7 (axial); while for **12d**, H-3 and Me-3a; H-7a, Me-3a and H-4 (geminal with the acetoxy group); H-5 and Me-7 (axial)].

The D-ring ketone of **12a** and **12b** was reduced to *sec*-alcohol by treatment with 9-BBN (Scheme 3),[22] subsequent dehydoxylation of this *sec*-alcohol with thionychloride in pyridine afforded the desired olefin, which upon hydrolysis of the diacetyl functionalities with potassium carbonate gave dihydroxyolefin **13** in 19% overall yield from **12**. Selective protection of dihydroxyolefin **13** using TBSOTf at −78 °C provided the 7-TBS protected compound in 19% yield. The hydroxyl group at C-6 was oxidized by Dess-Martin's reagent, which on subsequent deprotection of the silyl group with TBAF, followed by acetylation with acetic anhydride in pyridine, and epoxydation of olefin with *m*-chloroperbenzoic acid granted **14** in 14% overall yield from **13** (Scheme 3).

To determine **14**'s relative stereochemistry we again looked to the 2D-ROESY spectrum (Fig. 6). We could see a ROESY correlation between H-3 (geminal with the phenyl group) and Me-3a (the angular methyl group), H-4 (geminal with the acetoxy group) and H-6 (equatorial).

To investigate the potential bioactivity of epoxide **14**, we utilized the mouse lethality assay (MLA).[8d] This assay is considered the "gold standard" for the field and is used to assess any new protein or small molecule that may possess anti-botulinum activity. Before the assay was initiated with **14**, we first investigated potential toxicity issues with this molecule. Gratifyingly, at a concentration of 2.5 mM this compound showed no propensity to be toxic with any of the animals it was administered, n = 4. Thus, mice were injected iv with **14** followed immediately by ip injection of approximately 10LD_{50}s of BoNT/A. The mice were observed over a 48 hours period and unfortunately all mice succumbed to BoNT/A toxicity. In contrast the natural product toosendanin at this same concentration extended time to death 7.1 hours.

3. Conclusions

The work reported was initiated with a goal of using FOS as a strategy to begin to unravel toosendanins powerful anti-botulinum properties. Thus, a new synthetic approach to a 4-acetoxy CD fragment analogue of Toosendanin was achieved from mesityl oxide and acetylacetone in 14-steps. Unfortunately, this molecule provided no efficacy *in vivo*. However, we note that our synthetic route should allow access to other CD ring analogs, for example exchange of benzaldehyde to other aldehydes, would allow entry into other unnatural analogues. In addition, an acetyl group functional change would also provide another series of FOS-molecules. These compounds as well as the AB ring synthesis will be reported in due course.

4. Experimental

In general, reagents and solvents were used as purchased without further purification. All flash column chromatography was performed using silica gel 60 (230–400 mesh). Analytical and preparative thin-layer chromatography (TLC) was performed using Merck Kieselgel 60 F254 silica gel plates (0.25, 0.5, or 1 mm). ^{1}H NMR spectra was recorded on Bruker DRX-600 (600 MHz), DRX-500 (500 MHz), or Varian Inova-400 (400 MHz) spectrometers. ^{13}C NMR spectra was recorded on Bruker DRX-600 (150 MHz) spectrometer. All 2D-ROESY experiments (τ_m = 200ms) were also recorded on Bruker DRX-600 (600 MHz) spectrometer. Chemical shifts were reported in parts per million (ppm) on the δ scale from an internal standard (NMR descriptions: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet). High-resolution mass spectra was recorded on an Agilent ESI-TOF mass spectrometer.

4.1. 1-(5-hydroxy-1,3,3-trimethyl-7-oxabicyclo[4.1.0]heptan-2-yl)ethanone (9)

m-Chloroperbenzoic acid (*m*CPBA) (77%, 107.5 mg, 0.48 mmol) was added to a solution of **8** (87.3 mg, 0.48 mmol) in CH_2Cl_2 (2 mL) at room temperature, and the mixture was stirred at room temperature for 12 hours. 5% Na_2SO_3 aq. was added and the resulting heterogeneous

mixture was vigorously stirred. The organic layer was separated, and the aqueous phase was extracted with CH_2Cl_2. The combined organic extracts were washed with 5% Na_2CO_3 aq. and brine, dried over Na_2SO_4. The solvent was evaporated under reduced pressure to leave an oil, which was purified by flash chromatography on SiO_2 with Et_2O–hexane (2:1, v/v) to give **9** (93.3 mg, 98%) as a colorless oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 4.09 (ddd, J = 10.2, 6.3, 2.4 Hz, 1H), 3.17 (d, J = 2.3 Hz, 1H), 2.49 (s, 1H), 2.29 (s, 3H), 1.78 (dd, J = 13.1, 10.4 Hz, 1H), 1.48–1.41 (m, 1H), 1.47 (s, 3H), 0.94 (s, 3H), 0.92 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 207.2, 66.1, 61.5, 60.5, 60.1, 37.2, 33.7, 32.5, 29.2, 26.9, 24.8; HRMS $[MH]^+$ calcd for $C_{11}H_{19}O_3$, 199.1329; Found, 199.1329.

4.2. (*E*)-1-(3,4-dihydroxy-2,6,6-trimethylcyclohex-1-enyl)-3-phenylprop-2-en-1-one (10)

Under argon atmosphere, NaOH (52.6 mg, 1.3 mmol) was added to a solution of **9** (130.3 mg, 0.66 mmol) and benzaldehyde (66.8 μL, 0.66 mmol) in EtOH (3 mL) at room temperature, and the mixture was stirred at room temperature for 13 hours. After evaporation of the solvent, the whole was made acidic by adding 1 N HCl under ice cooling and extracted with Et_2O. The extract was washed with brine, dried over Na_2SO_4, and evaporated under reduced pressure to leave an oil, which was purified by flash chromatography on SiO_2 with AcOEt–hexane (5:1, v/v) to give **10** (180.7 mg, 96%) as a colorless oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.59–7.54 (m, 2H), 7.48 (d, J = 16.2 Hz, 1H), 7.43–7.39 (m, 3H), 6.78 (d, J = 16.2 Hz, 1H), 4.04–3.97 (m, 2H), 1.86–1.76 (m, 1H), 1.77 (s, 3H), 1.63–1.53 (m, 1H), 1.23 (s, 3H), 1.06 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 201.2, 146.6, 144.0, 134.3, 130.9, 129.6, 129.0, 128.6, 127.7, 70.4, 66.7, 40.8, 36.3, 29.7, 29.5, 28.0, 19.1; HRMS $[MH]^+$ calcd for $C_{18}H_{23}O_3$, 287.1642; Found, 287.1648.

4.3. (3a*RS*,4*RS*,5*RS*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyl-3a,4,5,6,7,7a-hexahydro-1*H*-indene-4,5-diyl diacetate (11a), (3a*RS*,4*SR*,5*RS*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyl-3a,4,5,6,7,7a-hexahydro-1*H*-indene-4,5-diyl diacetate (11b), (3a*RS*,4*RS*,5*SR*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyl-3a,4,5,6,7,7a-hexahydro-1*H*-indene-4,5-diyl diacetate (11c), and (3a*RS*,4*SR*,5*SR*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyl-3a,4,5,6,7,7a-hexahydro-1*H*-indene-4,5-diyl diacetate (11d)

Under argon atmosphere, **10** (484.6 mg, 1.7 mmol) was dissolved in 48 mL of 10^{-1} M $HClO_4$/0.5 M Ac_2O/AcOEt reagent.[18] The solution was allowed to stand at room temperature for 63 hours. Saturated $NaHCO_3$ aq. was added to quench the reaction. The organic layer was separated, and the aqueous phase was extracted with AcOEt. The extract was washed with 5% Na_2CO_3 aq. and brine, dried over Na_2SO_4, and evaporated under reduced pressure to leave a solid. The residue was recrystallized from AcOEt–hexane to give a mixture of **11a** and **11b** (311.3 mg, 50%) as a colorless powder. The mother liquor was purified by p-TLC on SiO_2 with AcOEt–hexane (1:4, v/v) to give **11c** (109.0 mg, 17%) as a yellow oil and **11d** (77.8 mg, 12%) as a colorless oil in the order of elution. **11a**: ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.52–7.43 (m, 5H), 6.05 (s, 1H), 5.73 (d, J = 3.3 Hz, 1H), 4.91 (ddd, J = 11.1, 4.7, 3.4 Hz, 1H), 2.25 (s, 1H), 1.99 (s, 3H), 1.95–1.87 (m, 1H), 1.93 (s, 3H), 1.61–1.53 (m, 1H), 1.51 (s, 3H), 1.28 (s, 3H), 1.01 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) (mixture of **11a** and **11b**) δ: 208.5, 206.4, 180.7, 179.3, 170.7, 170.2, 170.0, 169.8, 136.3, 134.0, 133.2, 130.2, 130.0, 128.9, 128.2, 127.6, 127.3, 74.6, 71.9, 70.1, 68.4, 64.3, 63.7, 50.9, 50.4, 43.4, 39.2, 34.3, 33.9, 32.7, 32.3, 29.0, 25.9, 25.1, 22.2, 21.1, 20.9, 20.6, 20.0; HRMS $[MH]^+$ calcd for $C_{22}H_{27}O_5$, 371.1853; Found, 371.1854. **11b** (data obtained from the spectrum of mixture): ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.39–7.34 (m, 3H), 7.32–7.28 (m, 2H), 6.08 (s, 1H), 5.50 (d, J = 8.0 Hz, 1H), 5.14 (dt, J = 8.0, 2.1 Hz, 1H), 2.27 (s, 1H), 2.16–2.04 (m, 1H), 1.94 (s, 3H), 1.67 (s, 3H), 1.61–1.53 (m, 1H), 1.34 (s, 3H), 1.29 (s, 3H), 1.17 (s, 3H). **11c**: ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.44–7.37 (m, 5H), 6.27 (s, 1H), 5.65 (d, J = 2.1 Hz, 1H), 5.30 (ddd, J = 12.1, 5.5, 2.3 Hz, 1H), 2.12 (s, 1H), 2.00 (s, 3H), 1.93–1.83 (m, 1H), 1.75 (s, 3H), 1.60 (s, 3H), 1.58–1.51 (m, 1H), 1.40 (s, 3H), 1.27 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 205.5, 174.0, 170.7, 169.5, 134.0, 131.2, 129.8,

128.8, 127.7, 71.7, 68.6, 62.4, 51.6, 36.2, 33.5, 32.7, 28.7, 25.6, 21.0, 20.5; HRMS $[MH]^+$ calcd for $C_{22}H_{27}O_5$, 371.1853; Found, 371.1861. **11d**: ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.44–7.33 (m, 5H), 6.26 (s, 1H), 5.32 (d, J = 3.6 Hz, 1H), 5.05 (ddd, J = 9.3, 7.2, 3.6 Hz, 1H), 2.25 (s, 1H), 2.09–2.02 (m, 1H), 2.07 (s, 3H), 1.71 (s, 3H), 1.55–1.50 (m, 1H), 1.54 (s, 3H), 1.34 (s, 3H), 1.14 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 207.0, 177.5, 169.7, 169.3, 135.3, 132.2, 129.6, 128.6, 127.6, 75.9, 72.1, 63.4, 50.6, 41.6, 33.6, 33.0, 29.7, 28.4, 23.7, 21.2, 20.6; HRMS $[MH]^+$ calcd for $C_{22}H_{27}O_5$, 371.1853; Found, 371.1856.

4.4. (3*RS*,3a*SR*,4*RS*,5*RS*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyloctahydro-1*H*-indene-4,5 -diyl diacetate (12a) and (3*RS*,3a*SR*,4*SR*,5*RS*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyloctahydro-1*H*-indene-4,5 -diyl diacetate (12b)

A solution of **11a** and **11b** (34.0 mg, 0.09 mmol) in EtOH (2 mL) was hydrogenated in the presence of Pd-alumina (5 wt %, 34.0 mg) at room temperature, and 1 atom for 18 hours. Pd-alumina was filtered off, and the filtrate was evaporated under reduced pressure to leave an oil, which was purified by p-TLC on SiO_2 with Et_2O–hexane (1:1, v/v) to give a mixture of **12a** and **12b** (34.2 mg, 100%) as a colorless oil. **12a**: ^{1}H NMR (500 MHz, $CDCl_3$) δ: 7.32–7.19 (m, 5H), 5.37 (q, J = 4.0 Hz, 1H), 4.88 (d, J = 4.4 Hz, 1H), 2.99 (dd, J = 13.1, 8.1 Hz, 1H), 2.86 (dd, J = 18.8, 13.2 Hz, 1H), 2.56 (dd, J = 18.8, 8.2 Hz, 1H), 2.16 (s, 1H), 1.98 (s, 3H), 1.78 (dd, J = 15.3, 3.9 Hz, 1H), 1.68–1.61 (m, 1H), 1.67 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H), 1.24 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) (mixture of **12a** and **12b**) δ: 214.8, 214.1, 170.5, 170.0, 169.9, 137.5, 136.3, 128.7, 128.2, 128.1, 127.1, 127.0, 71.6, 70.9, 69.2, 68.6, 66.7, 66.5, 50.7, 49.5, 49.0, 47.4, 41.1, 40.9, 40.6, 38.5, 33.7, 32.5, 31.3, 30.3, 29.7, 28.9, 23.2, 23.1, 21.2, 21.0, 20.3; HRMS $[MH]^+$ calcd for $C_{22}H_{29}O_5$, 373.2009; Found, 373.2006. **12b** (data obtained from the spectrum of mixture): ^{1}H NMR (500 MHz, $CDCl_3$) δ: 7.32–7.18 (m, 5H), 5.16–5.09 (m, 1H), 5.04 (d, J = 9.5 Hz, 1H), 3.06–2.90 (m, 2H), 2.58–2.51 (m, 1H), 2.05 (d, J = 1.5 Hz, 1H), 1.92 (s, 3H), 1.65–1.61 (m, 2H), 1.59 (s, 3H), 1.40 (s, 3H), 1.25 (s, 3H), 1.19 (s, 3H).

4.5. (3*RS*,3a*SR*,4*RS*,5*SR*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyloctahydro-1*H*-indene-4,5 -diyl diacetate (12c)

A solution of **11c** (102.7.0 mg, 0.28 mmol) in MeOH (6 mL) was hydrogenated in the presence of Pd-carbon (10 wt %, 50.5 mg) at room temperature, and 1 atom for 21 hours. Pd-carbon was filtered off, and the filtrate was evaporated under reduced pressure to leave an oil, which was purified by p-TLC on SiO_2 with AcOEt–hexane (1:3, v/v) to give **12c** (89.9 mg, 87%) as a colorless oil. ^{1}H NMR (600 MHz, $CDCl_3$) δ: 7.33–7.29 (m, 2H), 7.28–7.24 (m, 1H), 7.14–7.10 (m, 2H), 5.13 (ddd, J = 12.7, 4.4, 2.2 Hz, 1H), 4.71 (d, J = 1.9 Hz, 1H), 3.23–3.18 (m, 1H), 2.82 (dd, J = 18.8, 12.0 Hz, 1H), 2.56 (ddd, J = 18.7, 10.4, 1.0 Hz, 1H), 2.14 (s, 3H), 1.97–1.89 (m, 2H), 1.86 (s, 3H), 1.55 (s, 3H), 1.53 (s, 3H), 1.33 (dd, J = 12.9, 4.4 Hz, 1H), 1.21 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 213.6, 170.5, 169.0, 135.4, 129.0, 128.3, 127.6, 72.8, 68.9, 62.8, 50.7, 49.1, 42.3, 36.0, 33.7, 31.2, 29.4, 26.2, 21.7, 20.9; HRMS $[MNa]^+$ calcd for $C_{22}H_{28}O_5Na$, 395.1829; Found, 395.1829.

4.6. (3*RS*,3a*SR*,4*SR*,5*SR*,7a*SR*)-3a,7,7-trimethyl-1-oxo-3-phenyloctahydro-1*H*-indene-4,5 -diyl diacetate (12d)

A solution of **11d** (135.7 mg, 0.37 mmol) in MeOH (6 mL) was hydrogenated in the presence of Pd-carbon (10 wt %, 60.5 mg) at room temperature, and 1 atom for 21 hours. Pd-carbon was filtered off, and the filtrate was evaporated under reduced pressure to leave an oil, which was purified by p-TLC on SiO_2 with AcOEt–hexane (1:3, v/v) to give **12d** (82.5 mg, 61%) as a colorless oil. ^{1}H NMR (500 MHz, $CDCl_3$) δ: 7.35–7.30 (m, 2H), 7.29–7.20 (m, 3H), 4.87–4.80 (m, 1H), 4.24 (s, 1H), 3.23 (dd, J = 13.9, 8.2 Hz, 1H), 3.04 (dd, J = 17.6, 13.9 Hz, 1H), 2.51 (ddd, J = 17.6, 8.2, 1.6 Hz, 1H), 2.15 (s, 1H), 2.07 (s, 3H), 2.02–1.95 (m, 1H), 1.99 (s, 3H),

1.58–1.48 (m, 1H), 1.56 (s, 3H), 1.28 (s, 3H), 1.19 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 216.7, 169.2, 168.2, 136.3, 128.4, 127.4, 75.5, 72.0, 62.8, 51.3, 46.7, 43.9, 39.3, 34.6, 32.1, 29.7, 28.4, 24.8, 21.7, 21.1; HRMS $[MNa]^+$ calcd for $C_{22}H_{28}O_5Na$, 395.1829; Found, 395.1834.

4.7. (1*RS*,6*RS*,7*RS*,7a*SR*)-4,4,7a-trimethyl-1-phenyl-2,4,5,6,7,7a-hexahydro-1*H*-indene-6, 7-diol (13)

To a solution of **12a** and **12b** (935.0 mg, 2.5 mmol) in THF (20 mL) was slowly added 9-BBN (0.5 M, 10 mL, 5.0 mmol). The reaction mixture was stirred under argon atmosphere at room temperature for 4 hours, and then MeOH (10 mL) was slowly added, stirring for 3 hours. Removal of the solvent afforded a crude product. To a solution of crude product in CH_2Cl_2 (10 mL) at 0 °C under argon atmosphere were added pyridine (0.8 mL, 10 mmol) and $SOCl_2$ (0.4 mL, 5.0 mmol). The reaction mixture was stirred at room temperature for 12 hours, and then poured into ice-water. The organic layer was separated, and the aqueous phase was extracted with CH_2Cl_2. The whole was washed with 5% Na_2CO_3 and brine, dried over Na_2SO_4. Removal of the solvent afforded a crude product, which was purified by flash chromatography on SiO_2 with AcOEt–hexane (1:7, v/v) to give diacetoxyolefin. 1 N aqueous solution of K_2CO_3 (3 mL) was added to a solution of diacetoxyolefin in MeOH (10 mL) and CH_2Cl_2 (2 mL) at room temperature, and the mixture was stirred at room temperature for 86 hours. After evaporation of the solvent, the whole was made acidic by adding 2 N HCl under ice cooling and extracted with AcOEt. The extract was washed with brine, dried over Na_2SO_4, and evaporated under reduced pressure to leave an oil, which was purified by flash chromatography on SiO_2 with AcOEt–hexane (1:4, v/v) to give **13** (128.6 mg, 19%, 3 steps from mixture of **12a** and **12b**) as a colorless amorphous. ^{1}H NMR (600 MHz, $CDCl_3$) δ: 7.28–7.16 (m, 5H), 5.65–5.59 (m, 1H), 3.88 (q, J = 3.6 Hz, 1H), 3.14 (dd, J = 7.9, 1.7 Hz, 1H), 3.08 (d, J = 3.6 Hz, 1H), 2.92 (ddd, J = 16.8, 7.9, 1.7 Hz, 1H), 2.43–2.38 (m, 1H), 1.80 (dd, J = 14.6, 3.3 Hz, 1H), 1.51 (s, 3H), 1.33 (s, 3H), 1.27 (dd, J = 14.7, 3.6 Hz, 1H), 1.16 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 154.9, 144.9, 128.4, 128.0, 126.5, 122.2, 72.2, 72.0, 57.0, 55.8, 43.3, 37.3, 33.0, 32.1, 30.9, 23.3; HRMS $[MNa]^+$ calcd for $C_{18}H_{24}O_2Na$, 295.1668; Found, 295.1665.

4.8. (1*SR*,3*RS*,3a*RS*,4*RS*,7a*RS*)-4-Acetoxy-1,7a-epoxy-3-phenyl-3a,7,7-trimethyl-1,2,3a,4,7, 7a-hexahydro-3*H*-inden-5-one (14)

To a solution of **13** (115.9 mg, 0.43 mmol) in CH_2Cl_2 (5 mL) at −78 °C under argon atmosphere were added diisopropylethylamine (DIPEA) (0.1 mL, 0.86 mmol) and *t*-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf) (98%, 0.2 mL, 0.86 mmol). The reaction mixture was stirred at −78 °C for 2.5 hours. After addition of H_2O, the whole was extracted with CH_2Cl_2. The extract was washed with brine, dried over Na_2SO_4, and evaporated under reduced pressure to leave an oil, which was purified by p-TLC on SiO_2 with AcOEt–hexane (1:9, v/v) to give 7-TBS protected product which was desired (30.6 mg, 19%) as a colorless oil, 6-TBS protected product (69.0 mg, 42%) as a colorless oil, and unreacted **13** (25.8 mg, 22%) as a colorless oil in the order of elution. To a solution of 7-TBS protected product (30.6 mg, 0.08 mmol) in CH_2Cl_2 (3 mL) at room temperature under argon atmosphere was added Dess-Martin reagent (97%, 41.6 mg, 0.1 mmol). The reaction mixture was stirred at room temperature for 13 hours. After addition of saturated $NaHCO_3$ aq., the whole was extracted with CH_2Cl_2. The extract was washed with brine, dried over Na_2SO_4, and evaporated under reduced pressure to leave an oil. To a solution of crude oil in THF (2 mL) at room temperature under argon atmosphere was added TBAF (1.0 M, 0.1 mL, 0.12 mmol). The reaction mixture was stirred at room temperature for 2.5 hours. Removal of the solvent afforded a crude product, which was purified by p-TLC on SiO_2 with AcOEt–hexane (1:9, v/v) to give 7-hydroxyketone (16.0 mg, 75%, 2 steps from 7-TBS protected product) as a colorless oil. To a solution of 7-hydroxyketone (16.0 mg, 0.06 mmol) in pyridine (0.5 mL) at room temperature were added Ac_2O (0.25 mL) and

catalytic amount of 4-dimethylaminopyridine (DMAP). The reaction mixture was stirred at room temperature for 24 hours. Removal of the solvent afforded a crude product, which was purified by p-TLC on SiO_2 with AcOEt–hexane (1:7, v/v) to give 7-acetoxyketone (17.8 mg, 96%) as a colorless oil. *m*CPBA (77%, 15.3 mg, 0.07 mmol) was added to a solution of 7-acetoxyketone (17.8 mg, 0.06 mmol) in CH_2Cl_2 (1.0 mL) at room temperature, and the mixture was stirred at room temperature for 6 hours. 5% Na_2SO_3 aq. was added and the resulting heterogeneous mixture was vigorously stirred. The organic layer was separated, and the aqueous phase was extracted with CH_2Cl_2. The combined organic extracts were washed with 5% Na_2CO_3 aq. and brine, dried over Na_2SO_4. The solvent was evaporated under reduced pressure to leave an oil, which was purified by p-TLC on SiO_2 with AcOEt–hexane (1:5, v/v) to give **14** (18.7 mg, 14%, 5 steps from **13**) as a colorless amorphous: ^{1}H NMR (600 MHz, $CDCl_3$) δ: 7.30–7.25 (m, 2H), 7.25–7.19 (m, 1H), 7.17–7.12 (m, 2H), 5.07–5.06 (m, 1H), 3.80 (s, 1H), 2.85 (dd, J = 10.5, 8.3 Hz, 1H), 2.59 (d, J = 13.2 Hz, 1H), 2.42 (d, J = 13.2 Hz, 1H), 2.37–2.27 (m, 2H), 1.36 (s, 3H), 1.23 (s, 3H), 1.16 (s, 3H), 1.00 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ: 202.4, 169.6, 138.0, 128.6, 128.3, 127.0, 76.2, 70.9, 61.2, 51.3, 50.5, 50.0, 36.5, 30.1, 27.4, 24.3, 19.6, 17.3; HRMS $[MH]^+$ calcd for $C_{20}H_{25}O_4$, 329.1747; Found, 329.1750.

Acknowledgements

This work was supported by National Institute of Health (NIH) grant (AI 072358) and The Skaggs Institute for Chemical Biology.

6. References and notes

1. Johnson EA, Bradshaw M. Toxicon 2001;39:1703. [PubMed: 11595633]
2. Schantz EJ, Johnson EA. Microbiol Rev 1992;56:80. [PubMed: 1579114]
3. Simpson L. Annu Rev Pharmacol Toxicol 2004;44:167. [PubMed: 14744243]
4. Dickerson TJ, Janda KD. ACS Chem Biol 2006;1:359. [PubMed: 17163773]
5. Madsen JM. Clin Lab Med 2001;21:593. [PubMed: 11577702]
6. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. JAMA 1997;278:412. [PubMed: 9244333]
7. Zilinskas RA. JAMA 1997;278:418. [PubMed: 9244334]
8. (a) Èapková K, Yoneda Y, Dickerson TJ, Janda KD. Bioorg Med Chem Lett 2007;17:6463. [PubMed: 17951059] (b) Boldt GE, Eubanks LM, Janda KD. Chem Commun 2006:3063. (c) Boldt GE, Kennedy JP, Janda KD. Org Lett 2006;8:1729. [PubMed: 16597152] (d) Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, Baldwin MR, Malizio CJ, Goodnough MC, Barbieri JT, Johnson EA, Boger DL, Dickerson TJ, Janda KD. Proc Natl Acad Sci USA 2007;104:2602. [PubMed: 17293454] (e) Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzipori S, Janda KD, Allen KN. ACS Chem Biol 2007;14:533.
9. Nakatani M. Heterocycles 1999;50:595.
10. Carpinella C, Ferrayoli C, Valladares G, Defago M, Palacios S. Biosci Biotechnol Biochem 2002;66:1731. [PubMed: 12353636]
11. Xie YS, Fields PG, Isman MB, Chen WK, Zhang X. J Stored Prod Res 1995;31:259.
12. (a) Akhtar Y, Isman MB. J Chem Ecol 2003;29:1853. [PubMed: 12956511] (b) Carpinella MC, Defago MT, Valladares G, Palacios SM. J Agric Food Chem 2003;51:369. [PubMed: 12517097] (c) Zhou JB, Minami Y, Yagi F, Tadera K, Nakatani M. Heterocycles 1997;45:1781.
13. (a) Li P, Zou J, Miao W, Ding F, Meng J, Jai G, Li J, Ye H, He X. Zhongcaoyao 1982;13:28. (b) Zou J, Miao W, Ding F, Meng J, Ye H, Jia G, He X, Sun G, Li P. J Trad Chin Med 1985;5:29.
14. Wender PA, Verma VA, Paxton TJ, Pillow TH. Acc Chem Res 2008;41:40. [PubMed: 18159936]
15. Paquette LA, Hong FT. J Org Chem 2003;68:6905. [PubMed: 12946130]
16. Fernandez-Mateos A, Martin de la Nava EM, Pascual Coca G, Rubio Gonzalez R, Ramos Silvo AI, Simmonds MSJ, Blaney WM. J Org Chem 1998;63:9440.
17. Fernandez-Mateos A, Martin de la Nava EM, Rabanedo Clemente R, Rubio Gonzalez R, Simmonds MSJ. Tetrahedron 2005;61:12264.

18. Fernandez-Mateos A, Martin de la Nava EM, Rubio Gonzalez R. Tetrahedron 2001;57:1049–1057.
19. Fernandez-Mateos A, Pascual Coca G, Rubio Gonzalez R, Tapia Hernandez C. J Org Chem 1996;61:9097.
20. Fernandez-Mateos A, Lopez Barba AM. J Org Chem 1995;60:3580.
21. Fernandez-Mateos A, Lopez Barba A, Pascual Coca G, Rubio Gonzalez R, Tapia Hernandez C. Synthesis 1997:1381.
22. Fernandez-Mateos A, Mateos Buron L, Martin de la Nava EM, Rubio Gonzalez R. J Org Chem 2003;68:3585. [PubMed: 12713364]
23. Fernandez-Mateos A, Lopez Barba AM, Martin De La Nava E, Pascual Coca G, Perez Alonso JJ, Ramos Silvo AI. Tetrahedron 1997;53:14131.



1 **2**

Figure 1.
General structure of a Limonoid **1** and Toosendanin **2**.



Figure 2.
Toosendanin's core ring system **3**.



4

Figure 3.
Limonoid fragment synthesized by Mateos, et al. **4**.



Figure 4.
Nazarov electrocyclization reaction of **a–d**.



Figure 5.
The relative stereochemistry of compounds **12a–d** was determined by 2D-ROESY experiments.



14

Figure 6.
The relative stereochemistry of compound **14** was determined by 2D-ROESY experiment.



Scheme 1.

Synthesis of compound **10**. Reagents and conditions: (a) $BF_3{\cdot}Et_2O$, 5 °C; (b) $NaBH_4$, $CeCl_3{\cdot}7H_2O$, MeOH, −40 °C; (c) *m*CPBA, CH_2Cl_2, rt; 12 h, 98% (d) PhCHO, NaOH, EtOH, rt, 13 h, 96%.



Scheme 2.
Synthesis of compounds **12a–d**. Reagents and conditions: (a) 10^{-1} M $HClO_4$/0.5 M Ac_2O/AcOEt, rt, 63 h; (b) Pd-alumina, EtOH, rt, 18 h; (c) Pd-carbon, MeOH, rt, 21 h.



Scheme 3.

Synthesis of compound **14**. Reagents and conditions: (a) 9-BBN, THF, rt, 4 h; (b) $SOCl_2$, Pyridine, CH_2Cl_2, rt, 12 h; (c) K_2CO_3, MeOH, rt, 86 h, 19% for three steps; (d) TBSOTf, DIPEA, CH_2Cl_2, −78 °C, 2.5 h; (e) Dess-Martin reagent, CH_2Cl_2, rt, 13 h; (f) DMAP, rt, 24 h; (h) *m* TBAF, THF, rt, 2.5 h; (g) Ac_2O, Pyridine, *cat.* CPBA, CH_2Cl_2, rt, 6 h, 14% for five steps.